NS398 reduces hypoxia-inducible factor (HIF)-1alpha and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms

International Journal of Cancer. Journal International Du Cancer
Hua ZhongJonathan Simons

Abstract

Tissue hypoxia is a common feature in solid tumors. Hypoxia-inducible factor 1 (HIF-1) is a critical transcription factor that regulates the expression of genes encoding factors that influence tumor growth including vascular endothelial growth factor. Previous studies have demonstrated that post-transcriptional modification events are important for regulation of HIF-1alpha protein expression and HIF-1 transcriptional activity. Prostaglandin E2 (PGE2), a major end product of the cyclooxygenase-2 (COX-2) enzyme, induces the basal and hypoxia-induced nuclear relocalization of HIF-1alpha. This is suppressed by NS398, a COX-2 selective inhibitor. NS398 also inhibits hypoxia-induced angiogenesis, which may be mediated by the inhibition of HIF-1 function in a COX-2-dependent manner. Here, we show that NS398 reduces HIF-1alpha and HIF-1 transcriptional function in both COX-2 positive PC-3 cells and COX-2 negative HCT116 cells under normoxic and hypoxic conditions. On the one hand, NS398 decreases the expression of HIF-1alpha mRNA and reduces HIF-1alpha synthesis in a COX-2/PGE2 dependent way, which can be restored by addition of exogenous PGE2 that activates the phosphatidylinositol 3-kinase/AKT/p70s6k signaling pathway. On the other h...Continue Reading

Citations

Sep 7, 2007·Breast Cancer Research and Treatment·Yutaka YamamotoHirotaka Iwase
Apr 7, 2007·Cancer Metastasis Reviews·Giovanni Melillo
Aug 28, 2009·Expert Reviews in Molecular Medicine·Evon PoonMargaret Ashcroft
Jun 4, 2011·Leukemia·S K MartinA C W Zannettino
Jul 4, 2012·Antioxidants & Redox Signaling·Samar BasuMarie-Paule Vasson
Nov 4, 2006·Biological Chemistry·Andrea Huwiler, Josef Pfeilschifter
Nov 7, 2013·Evidence-based Complementary and Alternative Medicine : ECAM·Dae-Seung KimSeung-Heon Hong
Mar 22, 2006·Expert Opinion on Therapeutic Targets·Gregg L Semenza
Apr 9, 2011·International Journal of Radiation Biology·Keng-Li LanSang-Hue Yen
Jun 28, 2015·Cancer Letters·Ganji Purnachandra NagarajuBassel F El-Rayes
Aug 30, 2008·International Journal of Cancer. Journal International Du Cancer·Sanjeewani T PalayoorC Norman Coleman
Apr 19, 2011·International Journal of Cancer. Journal International Du Cancer·Indu SinhaRaghu Sinha
Mar 11, 2006·Biochemical and Biophysical Research Communications·Kyung Jin WooTaeg Kyu Kwon
Jun 28, 2005·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Nancy A LouisSean P Colgan
Apr 4, 2017·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Yung-Chuan HoYu-Chao Chang
Mar 1, 2017·Physiological Reports·Kui XuJoseph C LaManna
Jan 20, 2018·International Journal of Molecular Sciences·Adriano AngelucciCorrado Ficorella
Jun 4, 2005·The Journal of Pharmacology and Experimental Therapeutics·James P LuyendykRobert A Roth

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.